Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Status:
Recruiting
Trial end date:
2023-01-04
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well donor peripheral blood stem cell (PBSC) transplant works
in treating patients with hematologic malignancies. Cyclophosphamide when added to tacrolimus
and mycophenolate mofetil is safe and effective in preventing severe graft-versus-host
disease (GVHD) in most patients with hematologic malignancies undergoing transplantation of
bone marrow from half-matched (haploidentical) donors. This approach has extended the
transplant option to patients who do not have matched related or unrelated donors, especially
for patients from ethnic minority groups. The graft contains cells of the donor's immune
system which potentially can recognize and destroy the patient's cancer cells
(graft-versus-tumor effect). Rejection of the donor's cells by the patient's own immune
system is prevented by giving low doses of chemotherapy (fludarabine phosphate and
cyclophosphamide) and total-body irradiation before transplant. Patients can experience low
blood cell counts after transplant. Using stem cells and immune cells collected from the
donor's circulating blood may result in quicker recovery of blood counts and may be more
effective in treating the patient's disease than using bone marrow.